Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure

Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.